ImmuCell Appoints New Directors and Restructures Board for Innovation
ImmuCell Corporation announces the appointment of Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, effective April 15, 2026, as part of a strategic move to enhance its innovation strategy. The new board structure will consist of seven members, including six independent directors, aimed at improving governance and supporting the growth of First Defense products.
Theia Market Signal Identification - AI Assisted
Effective April 15, 2026, ImmuCell Corporation will restructure its Board of Directors to include seven members, six of whom will be independent. Dr. Gilles Guillemette and Dr.
Anthony DiMarco have been appointed to enhance the board's expertise in animal health strategy and manufacturing processes. The company is creating a Strategy and Technology Committee to drive innovation and technical development for its First Defense product line.
Bryan Gathagan, Michael Brigham, and Bobbi Brockmann will retire from the board, while Timothy Fiori will retire after the 2026 Annual Meeting. This restructuring is designed to improve corporate governance and accelerate growth.
Comments